三个皮匠报告—— 严选型全行业研究报告分享下载平台，您的专属行业智库！
欢迎来到三个皮匠报告！
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置：
首页
>
行业数据
>
主要癌症PIK3突变几率
主要癌症PIK3突变几率
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式：PNG
图片大小：66KB
图片尺寸：1876*1095
同报告图片
/
4
fCDnlr7nl4UgIHwg56qB5Y+Y5Yeg546HICB8CnwtLS0tLS0tLXwtLS0tLS0tLS18Cnwg6IKd55mMICAgIHwgMzUuNiUgICAgfAp8IOS5s+iFuueZjCAgIHwgMjYuMCUgICAgfAp8IOe7k+iCoOeZjCAgIHwgMjUuMCUgICAgfAp8IOiDg+eZjCAgICB8IDcuMCUgICAgIHwKfCDohJHnmYwgICAgfCA2LjAlICAgICB8Cnwg6IK655mMICAgIHwgMiUgICAgICAgfAoK6LWE5paZ5p2l5rqQOiBOYXR1cmUsIOS4reazsOWbvemZheeglOeptumDqA==
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
所属报告：
翰森制药-港股公司研究报告-深入布局优质赛道创新升级赋能新里程-230316（35页）.pdf
打包全文图表
相关数据
图表28PIK3CA靶点产品的竞争格局
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
收藏
竞争格局
2024-04-23
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模（亿美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模（亿美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模（百万美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
1）乳腺癌药物需求广阔：根据国家癌症中心发布的 2022 年癌症报告，2016 年乳腺癌新发病例总数在主要癌症中排名第四，因此乳腺癌药物需求广阔。2）PIK3 抑制剂适用患者较多：公司 HS-10352 针对的靶点 PIK3 在乳腺癌患者中突变率高达 26.0%，适用患者较多。3）临床数据表明公司产品的疗效与安全性良好：根据公司在美国癌症研究协会（AACR）会议发布的 1 期临床数据，6 例 PIK3CA 突变患者中，ORR 为50.0%，9 个月无进展生存率(PFS 率)为 66.7%，有效性良好。安全性层面，18 例患者中仅两例发生较为严重的副作用（3 级高血糖），发生皮疹的患者为两例。相对比，全球首个获批的 PIK3 抑制剂诺华（NVS US）的 Alpelisib+氟维司群组在临床试验中表现出的客观缓解率（ORR）为 35.7%，PFS 为 9.1 个月，3-4 级皮疹与高血糖发生率分别为 20%与 33%。虽然 1 期临床病例数量较少并不能反映最终结果，但是从以上数据看 HS-10352 没有表现出劣势。4）目前国内还没有其他针对 PIK3 靶点药物获批，因此 HS-10352 如能成功上市，先发优势很强。目前全球获批用于乳腺癌治疗的同靶点产品仅诺华（NVS US）的Alpelisib，并且没有进入中国，因此如公司产品能顺利上市，先发优势明显。
行业数据
原图定位
当前图表所属：
翰森制药-港股公司研究报告-深入布局优质赛道创新升级赋能新里程-230316（35页）.pdf
三代EGFR-TKI制剂对比
2016年国内主要癌症新发病例数量（单位：万人）
公司肿瘤领域主要仿制药市场份额
：财务摘要（年结：12月31日；人民币百万元）
下载图片或Excel，需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利，扫码领取！
关注公众号『三个皮匠报告』，免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码？
验证即登录，未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》
研搜
0731-84720580
商务合作：really158d
下载Excel
下载图片
原图定位
打包全文图表
收藏
2024-04-23
原图定位
微信扫码登录
手机快捷登录
账号登录
